Headlines
Headlines

Charles River Dives Deep Into Cell and Gene Therapy With Cognate BioServices Acquisition

Wilmington, MA , February 17 2021 (Business Wire) — Charles River Laboratories International, Inc. (NYSE: CRL) announced today that it has signed a definitive agreement to acquire Cognate BioServices, Inc., a premier, cell and gene therapy contract development and manufacturing organization (CDMO), for approximately $875 million in cash, subject to customary closing adjustments. The transaction is expected to close by the end of the first quarter of 2021, subject to regulatory requirements and customary closing conditions. More

Read More »
Headlines
Headlines

Excision BioTherapeutics Completes $60 Million Financing to Advance CRISPR-Based Infectious Disease Programs

San Francisco, CA, February 17, 2021 (GLOBE NEWSWIRE) — Excision BioTherapeutics (“Excision”), a leading developer of potentially curative CRISPR anti-viral therapies to improve patient lives, today announced the completion of a $60 million financing. The proceeds will be used to advance Excision’s lead candidate, EBT-101, into a Phase 1/2 clinical trial in patients with chronic HIV infection. The financing will also support preclinical programs including EBT-103 targeting JC Virus for Progressive Multifocal Leukoencephalopathy (PML), EBT-104 for Herpes Simplex Virus, and EBT-107 for Hepatitis B. More

Read More »
Headlines
Headlines

Henry Schein One Appoints New Chief Executive Officer

American Fork, UT, February 16, 2021 (BUSINESS WIRE) — Henry Schein One, a joint venture of Henry Schein, Inc., and Internet Brands, has announced that Mike Baird will assume the role of Chief Executive Officer, leading all aspects of Henry Schein One’s business. In his new role of CEO, Mr. Baird will lead the organization in driving growth, developing more seamlessly integrated products, and advancing digital innovations that help customers build stronger practices and deliver quality care. More

Read More »
Headlines
Headlines

AIkido Pharma Inc. Announces $10 Million Bought Deal Offering Of Common Stock

New York NY, February 16 2021 (PRNewswire) — AIkido Pharma Inc. (Nasdaq: AIKI) (“AIkido” or the “Company”) today announced that it has entered into an underwriting agreement with H.C. Wainwright & Co. under which the underwriter has agreed to purchase on a firm commitment basis 6,250,000 shares of common stock of the Company at a price to the public of $1.60 per share, less underwriting discounts and commissions. The closing of the offering is expected to occur on or about February 19, 2021, subject to satisfaction of customary closing conditions. More

Read More »
Headlines
Headlines

Jim Schuermann, 25 Year Industry Veteran, Appointed President & Chief Executive Officer of Saluda Medical

Artarmon, Australia, February 12, 2021 (PRNewswire) — Saluda Medical Pty Limited (“Saluda Medical”), the market leader in the development of novel closed-loop spinal cord stimulation (SCS) for the treatment of chronic pain, today announced the appointment of Jim Schuermann as President & Chief Executive Officer. Mr. Schuermann joined Saluda Medical as President in June 2020. The company also announced that founder and CEO John Parker, PhD, will take on the new role of Chief Scientific Officer, while remaining on the company’s Board of Directors. More

Read More »
Headlines
Headlines

Sandoz $500M deal for GSK antibiotics

Basel, Switzerland, February 11, 2021 (Sandoz) – Sandoz, a Novartis division, has signed an agreement to acquire GSK’s cephalosporin antibiotics business, reinforcing its leading global position in antibiotics. More

Read More »
Headlines
Headlines

Apollo Endosurgery Announces CEO Transition

Austin, TX February 8, 2021 ( ACCESSWIRE ) — Apollo Endosurgery, Inc. (“Apollo”) (NASDAQ:APEN), a global leader in next-generation minimally invasive medical devices for gastrointestinal and bariatric procedures, announced today a planned CEO change. Effective March 1, 2021, Charles (Chas) McKhann will become CEO and a member of the Board of Directors. Current CEO Todd Newton will help facilitate an effective transition to Mr. McKhann and has agreed to serve as a consultant to the Company for up to 6 months following his transition. More

Read More »
Headlines
Headlines

Veracyte to Acquire Decipher Biosciences

South San Francisco and San Diego, CA, — (BUSINESS WIRE) — Veracyte, Inc. (Nasdaq: VCYT) and Decipher Biosciences, Inc., a commercial-stage precision oncology company focused on urologic cancers, today announced they have entered into a definitive agreement through which Veracyte will acquire Decipher, further solidifying Veracyte’s global leadership in the genomic cancer diagnostics market while accelerating revenue growth. More

Read More »
Headlines
Headlines

Jazz Pharmaceuticals to acquire GW Pharmaceuticals plc

Dublin and London, February 3, 2021 (PRNewswire) — Jazz Pharmaceuticals plc (Nasdaq: JAZZ) and GW Pharmaceuticals plc (Nasdaq: GWPH) today announced the companies have entered into a definitive agreement for Jazz to acquire GW for $220.00 per American Depositary Share (ADS), in the form of $200.00 in cash and $20.00 in Jazz ordinary shares, for a total consideration of $7.2 billion, or $6.7 billion net of GW cash. The transaction, which has been unanimously approved by the Boards of Directors of both companies, is expected to close in the second quarter of 2021. More

Read More »
Headlines
Headlines

Open Implants Announces Gregg M. Gellman as Chief Executive Officer

Woburn, MA., February 3, 2021 (Newswire.com) – The Board of Directors of Open Implants LLC is pleased to announce the appointment of Gregg M. Gellman as the organization’s new Chief Executive Officer. With more than 15 years of experience, leading and growing biomedical companies, Gellman brings a unique and strong skill set to the company. More

Read More »
Headlines
Headlines

Olympus acquires Quest Photonic Devices for $60.7 M

Tokyo/Hamburg, 28 January 2021 (Olympus) – Olympus Corporation (”Olympus” – Director, Representative Executive Officer, President and CEO: Yasuo Takeuchi) today announced that it has entered into an agreement to acquire Quest Photonic Devices B.V. (“Quest” – CEO: Richard Meester) for up to EUR50 million including milestone payments to strengthen its surgical endoscopy capabilities. More

Read More »
Headlines
Headlines

Titan Medical Announces Closing of US $11.5M Bought Deal Offering Including Full Exercise of Over-Allotment Option

Toronto, January 26 2021 (BUSINESS WIRE) — Titan Medical Inc. (“Titan” or the “Company”) (TSX: TMD) (Nasdaq: TMDI), a medical device company focused on the design and development of surgical technologies for robotic single access surgery, announced today that it closed its previously announced offering of 6,451,613 units of the Company (“Units”) sold on a “bought deal” basis for gross proceeds of approximately US $10,000,000.00 (the “Offering”). More

Read More »